Bruker (BRKR) pre-announced Q2 revenue that fell below consensus estimates, with organic revenue down 7% year over year and constant currency revenue down 3%, reflecting continued weakness in academic demand and softness in the U.S. biopharma market, both of which weighed on bookings, Stifel analyst Daniel Arias tells investors in a research note. The firm, which has a Hold rating on the shares, says key focus areas will include order trends across academic and biopharma channels and any revisions to the FY25 outlook, given that Q2 organic revenue growth and adjusted EPS tracked below the current full-year guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker reports preliminary Q2 EPS 32c-34c, consensus 43c
- Bruker price target lowered to $50 from $61 at BofA
- NIH directs staff not to end any extra research projects for now, NY Times says
- Bruker’s Growth Potential Driven by Innovations and Strategic Cost Management
- Bruker acquires biocrates life sciences, terms undisclosed